

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8202936

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH	08/21/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	
<b>Street Address:</b>	BINGER STRASSE 173	
<b>City:</b>	INGELHEIM AM RHEIN	
<b>State/Country:</b>	GERMANY	
<b>Postal Code:</b>	55216	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	17283285
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(203)837-5616	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(203)448-1844	
<b>Email:</b>	USPTO.e-Office.rdg@boehringer-ingelheim.com	
<b>Correspondent Name:</b>	BOEHRINGER INGELHEIM USA CORPORATION	
<b>Address Line 1:</b>	900 RIDGEBURY RD, P.O. BOX 368	
<b>Address Line 4:</b>	RIDGEFIELD, CONNECTICUT 06877	
<b>ATTORNEY DOCKET NUMBER:</b>	21-0012-US-2	
<b>NAME OF SUBMITTER:</b>	ALISON MONTUORO	
<b>SIGNATURE:</b>	/Alison Montuoro/	
<b>DATE SIGNED:</b>	10/04/2023	
<b>Total Attachments: 2</b>		
source=21-0012-US-2-BIOPHARMA-BII-WWAssignment-Signed-All#page1.tif		
source=21-0012-US-2-BIOPHARMA-BII-WWAssignment-Signed-All#page2.tif		

**CONFIRMATION OF ASSIGNMENT / ASSIGNMENT -- WORLDWIDE**

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and further pursuant to one or more intercompany agreements, Boehringer Ingelheim Biopharmaceuticals GmbH, with its principal place of business at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany ("Assignor") has previously transferred, sold, and assigned, and to the extent Assignor has not previously transferred, sold, and assigned hereby transfers, sells, and assigns, unto Boehringer Ingelheim International GmbH, a German corporation with its principal place of business at Binger Strasse 173, Ingelheim am Rhein, Germany 55216, ("Assignee"), its entire right, title, and interest, for the United States and the Territories and Possessions thereof and all foreign countries and regions, in and to the inventions and designs (if any) (hereinafter collectively referred to as the "Inventions") as set forth and described in the following United States patent application(s): Application No. 17/283,285 ; filed April 7, 2021 (hereinafter referred to as the "Application"), including all rights to provisionals, nonprovisionals, divisionals, continuations, continuations-in-part, Patent Cooperation Treaty (PCT) applications, and national stages of any such PCT applications, and all other foreign patent applications based in whole or in part upon the Inventions or upon the Application, and any and all Letters Patent and reissues, reexaminations, and extensions of Letters Patent granted in any country for the Inventions or upon the Application or any patent application claiming priority rights from the Application, and every priority right that is or may be predicated upon or arise from the Inventions, or from the Application, and including all rights to sue for any infringement of the Letters Patent, and further including all rights to past damages relating to third party infringement of the Letters Patent, the Assignee being hereby authorized to file and prosecute patent applications, including completing formalities and recordation of ownership claims, in any or all countries and regions on any or all of the Inventions in the name of the undersigned or in the name of the Assignee or otherwise as the Assignee may deem advisable, under the PCT or otherwise; the United States Patent and Trademark Office and corresponding patent granting authorities outside the United States being hereby authorized to issue or transfer all the Letters Patent issuing from any patent applications claiming the Inventions or claiming priority from the Application to the Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right heretofore given, and that the undersigned will do all acts reasonably serving to ensure that the Inventions, the Application, and any Letters Patent which may issue from any patent applications claiming the Inventions or claiming priority from the Application shall be held and enjoyed by the Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to the Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, declarations, and lawful affidavits in form

BI Employer to BII WWAssignment  
U.S. Serial No. 17/283,285  
Date of Filing: April 7, 2021

Attorney Docket No. 21-0012-US-2

and substance which may be requested by the Assignee, to furnish the Assignee with all facts relating to the inventions and/or the Application or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may embody the inventions or relate to the Application, and generally do everything possible to aid the Assignee, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection, in all countries and regions, for the inventions, the Application, and/or Letters Patent that may issue as a result of the Application and from any patent applications claiming priority to the Application, and not to take any action challenging or opposing, on any grounds whatsoever, Assignee's rights granted under this Agreement, or the validity of the transfer of the ownership rights hereunder. For the avoidance of doubt, nothing in this assignment requires the Assignor to provide testimony in a United States litigation related to the above mentioned inventions, Application, and/or Letters Patent.

The undersigned hereby grant(s) an authorized representative of Assignee the power to insert in this Assignment any further identification that may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office and/or corresponding patent granting authorities outside the United States, and to handle all correspondence relating to the Application or any patent applications claiming priority from the Application.


**NAME AND SIGNATURE OF THE AUTHORIZED OFFICERS OF ASSIGNEE (Employer)**


Ingelheim am Rhein, DE, on August 21, 2023

Boehringer Ingelheim Biopharmaceuticals GmbH

ppa.

ppa.

  
Clemens GRUPP

  
Malte FIDLER

*Authorized Signatories*


**NAME AND SIGNATURE OF THE AUTHORIZED OFFICERS OF ASSIGNEE**


Ingelheim am Rhein, DE, on August 24, 2023

Boehringer Ingelheim International GmbH

ppa.

I. V.

  
Dr. Markus WEYMANN

  
Sabine GERINGER

*Authorized Signatories*